Spinal Muscular Atrophy Market is expected to reach US$ 20.06 Billion by 2033 | Major players - F. Hoffmann-La Roche Ltd, Novartis AG, Biogen, Chugai Pharmaceutical Co., Ltd.

Market Size and Growth:

The Spinal Muscular Atrophy Market size reached US$ 4.40 Billion in 2024 and is expected to reach US$ 20.06 Billion by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033.

The Spinal Muscular Atrophy Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/spinal-muscular-atrophy-market?sz

The Spinal Muscular Atrophy Market encompasses therapies, drugs, and supportive interventions developed to manage spinal muscular atrophy, a rare genetic neuromuscular disorder. It includes gene therapies, antisense oligonucleotides, small-molecule drugs, and supportive care aimed at improving motor function, survival, and quality of life across pediatric and adult patients.

Recent Key Developments of United States:

✅ In November 2025, the FDA approved Itvisma (onasemnogene abeparvovec-brve) by Novartis as a gene replacement therapy for children aged two and older, teens, and adults with spinal muscular atrophy (SMA).​

✅ In November 2025, Scholar Rock held a constructive meeting with the FDA, paving the way for resubmission of its biologics license application for apitegromab, a muscle-targeting therapy to improve motor function in SMA patients on standard treatments.​

✅ In September 2025, a clinical trial reported encouraging results for a new muscle-targeting therapy aimed at enhancing motor function in children and young adults with SMA.

Recent Key Developments of Europe:

✅ In early December 2025, reports highlighted expanded gene therapy access for SMA patients of any age in the US, with EMA review of Novartis' intrathecal onasemnogene abeparvovec ongoing and expected in mid-2026.

✅ In November 2025, the CHMP issued a positive opinion recommending approval of a high-dose nusinersen (Spinraza) regimen for 5q SMA, with the European Commission expected to decide by January 2026; the DEVOTE study showed improved motor function and reduced mortality.

✅ Scholar Rock's marketing authorization application for apitegromab in SMA remains under EMA review, with a decision anticipated in mid-2026.

List of the Key Players in the Spinal Muscular Atrophy Market:

F. Hoffmann-La Roche Ltd
Novartis AG
Biogen
Chugai Pharmaceutical Co., Ltd.
PTC Therapeutics, Inc.
Eisai Co., Ltd.

Emerging Players:

NMD Pharma A/S

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/spinal-muscular-atrophy-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Spinal Muscular Atrophy Market:

By Type: SMA type 0 (Congenital SMA), SMA type 1 (Severe SMA), SMA type 2 (Intermediate SMA), SMA type 3 (Mild), SMA type 4 (Adult).

By Treatment: Disease-modifying Therapy, Gene Replacement Therapy.

By Route of Administration: Injectables, Oral.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=spinal-muscular-atrophy-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Spinal Muscular Atrophy market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Spinal Muscular Atrophy Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Spinal Muscular Atrophy market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Spinal Muscular Atrophy Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Spinal Muscular Atrophy Market in 2025?
◆ What is the projected growth rate of the Spinal Muscular Atrophy Market through 2033?
◆ Who are the key players in the Spinal Muscular Atrophy Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.